Veritas Aortic Solutions Secures $12M Seed Funding

Why It Matters

A minimally invasive, catheter‑based solution could dramatically lower mortality and expand treatment options for high‑risk patients who are unsuitable for traditional open‑heart surgery, reshaping the structural‑heart market.

Key Takeaways

• $12 million seed round led by Cedars‑Sinai IP Company.
• TVARC device combines valve, graft, and coronary perfusion ports.
• Catheter‑based approach targets high‑risk aortic root patients.
• Board adds former Medtronic CoreValve exec Chad Martinson.
• Funding accelerates regulatory prep and first human trials.

Pulse Analysis

The aortic root and ascending aorta represent some of the most complex and high‑mortality territories in cardiovascular surgery. Conventional repair requires sternotomy, cardiopulmonary bypass, and lengthy recovery, limiting eligibility for frail or comorbid patients. Industry analysts estimate the global market for aortic interventions exceeds $5 billion, with a growing segment seeking less invasive alternatives. Veritas Aortic Solutions’ TVARC system directly addresses this gap by offering a fully catheter‑based platform that merges a bioprosthetic valve, an ascending‑aorta graft, and its unique "Chameleon Eyes" coronary perfusion ports, all deployed through a small femoral access point.

Backed by Cedars‑Sinai’s intellectual‑property arm and the QB8 Medical Technologies incubator, Veritas benefits from both capital and deep clinical expertise. The involvement of seasoned executives like former Medtronic CoreValve leader Chad Martinson adds credibility and strategic guidance as the company moves from pre‑clinical work to human trials. The $12 million seed injection will fund regulatory‑grade manufacturing, expanded pre‑clinical testing, and the initiation of first‑in‑human studies, positioning Verita​s to meet FDA and European CE requirements on an accelerated timeline.

If clinical data confirm safety and efficacy, TVARC could unlock treatment for thousands of patients currently deemed inoperable, driving a shift toward endovascular solutions in structural heart disease. This would not only reduce procedural risk and hospital stays but also create a new revenue stream for device manufacturers and investors. The successful commercialization of TVARC may prompt larger players to pursue similar catheter‑based platforms, intensifying competition and fostering innovation across the cardiovascular device sector.

Deal Summary

Medical device startup Veritas Aortic Solutions announced the close of a $12 million seed round to fund development of its catheter-based TVARC system for non-surgical aortic disease treatment. The round was led by Cedars-Sinai Intellectual Property Company (CSIPCo) with participation from existing investors linked to the inQB8 Medical Technologies incubator. The capital will support pre-clinical validation and the launch of human clinical trials.